Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orchard Therapeutics Ltd.

www.orchard-tx.com

Latest From Orchard Therapeutics Ltd.

Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO

Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.

Deals StartUps and SMEs

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Financing Business Strategies

MedinCell Boosts Funding For Long-Acting Injectables Portfolio

France's long-acting injectables technology company, MedinCell, which is collaborating with Teva on a Phase III long-acting risperidone formulation, has completed an IPO on Euronext Paris, giving a lift to its development plans.

 

Neurology Financing

Orchard Cash Pile Set To Rise With Nasdaq IPO

The UK gene therapy firm was only set up in 2016 but after raising $260m in two financing rounds since the end of 2017, Orchard has filed documents with a view to listing on NASDAQ.

Financing Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Orchard Therapeutics Ltd.
  • Senior Management
  • Mark Rothera, Pres. & CEO
    Frank Thomas, CFO & CBO
    Andrea Spezzi, MD, CMO
    Bobby Gaspar, MD, CSO
    Adrien Lemoine, SVP, Bus. Dev. & Alliance Mgmt.
  • Contact Info
  • Orchard Therapeutics Ltd.
    Phone: 203 384 6700
    108 Cannon St.
    London, EC4N 6EU
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register